In this issue:
NUDT15 variants with thiopurineinduced myelosuppression in IBD
Infliximab biosimilar vs. originator in active CD
Predicting anti-TNF failure in active luminal CD
Early combined immunosuppression in elderly CD
Safety and effectiveness of anti-TNFα agents vs. vedolizumab in elderly IBD
IL-23R-bearing TNFR2+ T-cell expansion and anti-TNF resistance in CD
Consecutive colonoscopes for predicting advanced neoplasia risk in IBD with chronic colitis
Thiopurines’ impact on natural history and surgical outcomes in UC
Vedolizumab dose intensification for reversing loss of response in IBD
Transmural CD healing vs. mucosal/no healing: clinical outcomes
Please login below to download this issue (PDF)